52°
Congressman Luttrell expresses disappointment over FDA's rejection of MDMA for PTSD treatment
Aug 9, 2024
WASHINGTON -- Congressman Morgan Luttrell (R-TX) released a statement regarding the Food and Drug Administration's (FDA) rejection of MDMA as a treatment for post-traumatic stress disorder (PTSD). Despite mounting evidence supporting the effectiveness of psychedelic-assisted therapy in treating combat-related mental health injuries, the agency's decision represents a significant setback for those suffering from PTSD, particularly veterans who have exhausted conventional treatment options.
“I am deeply disappointed by the FDA's decision to reject MDMA as a treatment for PTSD. For many veterans, myself included, psychedelic treatment has shown life-changing results in treating combat-related mental health injuries, especially where conventional treatments, like opioids, have fallen short,” said Congressman Luttrell. “This decision is a major setback for those who are desperately seeking and deserve effective treatment options. However, I remain committed to advancing legislation that supports innovative therapies for PTSD. I will continue to work with my colleagues in Congress to ensure that we explore all avenues to provide the best possible care for those who have served our country so bravely."
Congressman Luttrell has been a leading advocate in the United States House of Representatives for emerging therapies to treat combat-related mental health injuries. He has sent multiple letters expressing his support for this treatment, the most recent of which he was joined by 60 House colleagues, and he recently penned an op-ed about psychedelic therapy.
###